Tburn

T-Burn is a Swiss biotechnology company focused on enhancing the efficacy of cancer immunotherapy through the metabolic reprogramming of T cells. The company leverages cutting-edge research in immunometabolism to identify and modulate metabolic checkpoints that typically lead to T cell exhaustion within the immunosuppressive tumor microenvironment. By improving the metabolic fitness and persistence of T cells, T-Burn aims to develop next-generation treatments for solid tumors. Their approach encompasses both the engineering of adoptive cell therapies and the development of pharmacological modulators to optimize immune cell function.